+86-21-58356573
LANGUAGE

Company news

Initiation Meeting of Phase I Clinical Trials of ImmuneOnco IMM01

2019-8-2 0:00:00Click:152

      On August 2, 2019, the Initiation meeting of phase I clinical trial of ImmuneOnco IMM01 project was held in the Hematological Hospital of the Chinese Academy of Medical Sciences. With IMM01 entering clinical research as the first experimental drug, it marks that ImmuneOnco has formally entered the clinical stage of entrepreneurship companies.




       Dr. Tian Wenzhi, founder of ImmuneOnco, and Director Qiu Lugui, Hospital of Hematology, Chinese Academy of Medical Sciences made opening remarks. Subsequently, the research team conducted in-depth and detailed discussions on the design of the research program, the work processes and key issues in the implementation of the research.



 

      Dr Tian Wenzhi said: "IMM01 is an IgG1 Fc fusion protein targeting human CD47. In animal model tests, it has been used alone to obtain better therapeutic effect. The macromolecule drugs targeting human CD47 abroad are currently in Phase I and Phase II stages, with a reported response rate of 68%. Our IMM01 does not bind to human red blood cells, and it is expected that no anemia will occur in theclinical trial. We look forward to the exciting results of phase I clinical trials of IMM01 project.

 

          

 

      Director Qiu Lugui said: "Drug research targeting CD47 will give us an additional weapon against cancer. Peripheral blood T-lymphoma and diffuse large B-lymphoma have few drugs available clinically. We hope that IMM01 will be included in the trial as soon as possible, and then continue to expand its indications in subsequent trials.


 

 

       About IMM01

       IMM01 is a new generation of immune checkpoint inhibitors with independent intellectual property rights based on the technology platform of "mAb-Trap" of ImmuneOnco. Aiming at CD47, the target of immune regulation, IMM01 activates the phagocytic effect of macrophages on tumor cells and presents the phagocytosis-treated tumor antigens to T cells, so as to play a strong role and large tumor immunotherapy effect. ImmuneOnco perfectly solved the core pain point of CD47 target drug research and development.

 

 

      About ImmuneOnco

      ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Shanghai Zhangjiang High-tech Park. The company is mainly committed to the development of immunotherapy products for cancer, including bispecific antibodies, new recombinant proteins, and CAR-NK cell therapy. The common feature of our products is to stimulate the immune system of patients to play an anti-tumor effect, and ultimately inhibit the growth of cancer cells, reversing the resulting series of malignant symptoms, so that patients gradually return to a healthy body state.

 

  

Contact us

Address: Room 502, 1043 Harley Road, Pudong New Area, Shanghai, China

Tel: +86 21 5835 6573

Website: www.immuneonco.com